Back to Journals » Journal of Pain Research » Volume 12

Pain reduction and improved vascular health associated with daily consumption of an anti-inflammatory dietary supplement blend

Authors Hamilton DE, Jensen GS

Received 28 September 2018

Accepted for publication 24 April 2019

Published 15 May 2019 Volume 2019:12 Pages 1497—1508

DOI https://doi.org/10.2147/JPR.S189064

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Katherine Hanlon


Debby E Hamilton,1 Gitte S Jensen2

1Researched Nutritionals, Los Olivos, CA, USA; 2NIS Labs, Klamath Falls 1437, OR, USA

Purpose: The objective for this clinical pilot study was to evaluate changes to chronic pain, vascular health, and inflammatory markers when consuming a dietary supplement blend (DSB, CytoQuel®), containing curcumin, resveratrol, tocotrienols, N-Acetylcysteine, and epigallocatechin gallate.
Materials and methods: An open-label study design was used where 21 study participants were evaluated at baseline and at 2 and 8 weeks after consuming DSB. Participants were randomized to consume 3 capsules once daily versus 2 capsules twice daily. Pain and activities of daily living questionnaires were used to gather subjective data on pain levels and interference with daily living. Blood pressure was measured in both arms and ankles, and the ankle-brachial index (ABI) calculated. Blood samples were used to evaluate markers associated with inflammation and cardiovascular health.
Results: Highly significant reduction of chronic pain was seen after 8 weeks (p<0.01), both at rest and when physically active. Faster improvement was seen when consuming 3 capsules once daily, compared to 2 capsules twice daily. The pain reduction resulted in improved sleep quality (p<0.1), and improved social functioning (p<0.01), and less need for support from others (p<0.05), Normalization of mildly elevated ABI at study start was seen after 2 weeks. Plasma fibrinogen and von Willebrand Factor and serum matrix metalloproteinase-9 (MMP-9) showed reduction after 2 weeks (not significant), whereas a reduction in serum interleukin-1 receptor antagonist-a (IL-1ra) was statistically significant after 2 weeks (p<0.05). Correlation between pain reduction and changes to MMP-9 after 8 weeks was highly significant (P<0.01), whereas correlation between pain reduction and changes to IL-1ra reached significance at 2 weeks for the group consuming 3 caps once daily (p<0.04).
Conclusion: Consuming DSB helped manage pain, increased comfort during daily activities, and improved vascular function. This was associated with selective effects on specific blood biomarkers associated with inflammation and vascular health.

Keywords: ankle-brachial index, cardiovascular disease, fibrinogen, interleukin-1 receptor antagonist, matrix metalloproteinase-9, von Willebrand factor


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]